Non-surgical periocular nodular-BCC treatments are successful

Article

Imiquimod (IMQ) 5% cream and radiotherapy (RT) are both effective for treating periocular nodular-based cell carcinoma (BCC)

Imiquimod (IMQ) 5% cream and radiotherapy (RT) are both effective for treating periocular nodular-based cell carcinoma (BCC), according to a study published in the British Journal of Ophthalmology.

Dr Elena Garcia-Martin et al., Hospital Universitario Miguel Servet, Zaragoza, Spain, examined 27 patients with clinical and histopathological diagnosis of nodular BCC on the eyelid. IMQ 5% cream was administered in 15 patients once daily 5 days a week for 6 weeks. RT was performed in 12 patients.

Within 3 months of treatment all patients demonstrated histopathological remission. Sustained clinical remission was recorded in every patient after 24 months follow-up. Toleration of treatment for IMQ and RT was recorded as moderate and good, respectively.

The investigation concluded that the non-surgical methods of using IMQ and RT were successful in treating eyelid nodular BCCs. IMQ demonstrated better cosmesis and functional results, whereas RT demonstrated a better tolerability.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.